Trevi Therapeutics Q2 2026 net loss $17.8M; cash $318.9M; Phase 3 OCEAN-1 initiated

Trevi Therapeutics, Inc.

Net loss of $17.8M in Q2 2026 vs $12.3M in Q2 2025; R&D expenses $15.2M (up from $9.4M).
Cash, cash equivalents and marketable securities $318.9M; April 2026 stock offering netted $162.3M; cash runway into 2030.
Initiated Phase 3 OCEAN-1 trial for IPF-related chronic cough; topline data expected H1 2028.
Initiated Phase 2b LAKE trial for refractory chronic cough; sample size re-estimation expected Q4 2026.
Submitted FDA meeting request for non-IPF ILD-related chronic cough development plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.